146
Views
27
CrossRef citations to date
0
Altmetric
Research Article

Clinical Significance of Anti-Multiple Nuclear Dots/Sp100 Autoantibodies

, , , , , , & show all
Pages 996-999 | Published online: 08 Jul 2009

  • Bernstein RM, Neuberger JM, Bunn CC, Callender ME, Hughes GRV, Williams R. Diversity of autoantibodies in primary biliary cirrhosis and chronic active hepatitis. Clin Exp Immunol 1984; 55:553-60.
  • Cassani F, Bianchi FB, Eenzi M, Volta U, Pisi E. Immunomorphological characterisation of antinuclear antibodies in chronic liver disease. J Clin Pathol 1985:38:801-5.
  • Powell F, Schroeter AL, Dickson ER. Antinuclear antibodies in primary biliary cirrhosis. Lancet 1984:1:288-9.
  • Fritzler MJ, Valencia DV, McCarthy GA. Speckled pattern antinuclear antibodies resembling anticentromere antibodies. Arthritis Rheum 1984:27:92-6.
  • Mzali S, Johanet C, Chrétien P, Abuaf N. Aiitinuclear antibodies in primary biliary cirrhosis. Gastroenterol Clin Biol 1998:3: 690-5.
  • Evans .1, Reuben A, Craft .1. PBC 95k, a 95-kilodalton nuclear autoantigen in primary biliary cirrhosis. Arthritis Rheum 1991; 34:731-6.
  • Szostecki C, Krippner H, Penner E, Bautz FA. Autoimmune sera recognize a 100kD nuclear protein antigen (Sp100). Clin Exp Immunol 1987:68:108-16.
  • Fusconi M, Cassani F, Govoni M, Casselli A, Farabegoli F, Lernzi M, et al. Anti-nuclear antibodies of primary biliary cirrhosis recognize 78-92 kD and 96-100 kD proteins of nuclear bodies. Clin Exp Immunol 1991:83:291-7.
  • Sternsdorf T, Guldner HH, Szostecki C, Grötzinger T, Will H. Two nuclear dot associated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis. Scand J Immunol 1995:42:257-68.
  • Hansen BU, Eriksson S, Lindgren S. High prevalence of autoimmune liver disease in patients with multiple nuclear dots, anti-centromere and mitotic spindle antibodies. Scand J Gastroenterol 1991:26:707-13.
  • Pawlotsky JM, Andre C, Metreau JM, Beaugrand M, Zafrani ES, Dhumeaux D. Multiple nuclear dots antinuclear antibodies are not specific for primary biliary cirrhosis. Hepatology 1992:16: 127-31.
  • Zuchner D, Sternsdorf T, Szostecki C, Heathcote EJ, Cauch-Dudek K, Will H. Prevalence, kinetics and therapeutic modulation of autoantibodies against Sp 100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology 1997:26:1 123-30.
  • Wichmann I, Respaldiza N, Garcia-Lozano JR, Montes M, Sanchez-Roman J, Nunez-Roldán A. Autoantibodies to DEK oncoprotein in systemic lupus erythematosus (SLE). Clin Exp Immunol 2000:119:530-2.
  • Dong X, Wang J, Kabir FN, Shaw M, Reed AM, Stein L, et al. Autoantibodies to DEK oncoprotein in human inflammatory disease. Arthritis Rheum 2000:43:85-93.
  • Russo K, Hoch S, Dima C, Varga J, Teodorescu M. Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erytematosus and rheumatoid arthritis. J Rheumatol 2000:27:142-8.
  • Seelig HP. Autoantibodies. Peter JB, Shoenfeld Y, editors. Elsevier Science: 1996. p. 591.
  • Taal BG, Schalm SW, Ten Kate Fibo WJ, Hermans J, Geertzen RGM, Feltkamp BEW. Clinical diagnosis of primary biliary cirrhosis: a classification based on major and minor criteria. Hepato-gastroenterol 1983:30:178-82.
  • Muratori P, Muratori L, Cassani F, Terlizzi P, Lenzi M, Rodrigo L, et al. Anti-multiple nuclear dots (anti-MND) and ant-Sp100 antibodies in hepatic and rheumatological disorders. Clin Exp Immunol 2002:127:172-5.
  • Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Hochberg MC. Arthritis Rheum 1997:40:1725.
  • Michieletti P, Wanless IR, Katz A, Scheuer PJ, Yeaman SJ, Bassendine MF, et al. Antimitocliondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune colangitis. Gut 1994:35:260-5.
  • Omagari K, Ikuno N, Matsuo I, Shirono K, Hara K, Feeny SJ, et al. Autoimmune cholangitis syndrome with a bias towards primary biliary cirrhosis. Pathology 1996:28:255-8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.